Effect of Fetuin A in Hemodialysis Patients
This trial is active, not recruiting.
|Sponsor||University of Shizuoka|
|Collaborator||Maruyama Memorial General Hospital|
|Start date||March 2001|
|End date||March 2006|
|Trial size||300 participants|
|Trial identifier||NCT00309426, CT2006003|
The purpose of this study is to examined the effect of fetuin A on atherosclerosis and prognosis in hemodialysis patients.
|Observational model||defined population|
Male or female participants up to 70 years old.
Inclusion Criteria: - Hemodialysis for at least 6 months Exclusion Criteria: - Disabled patients
|Official title||The Effect of Serum Fetuin A Concentration on the 5-Year Prognosis in Hemodialysis Patients|
|Description||Fetuin A is known to be a potent inhibitor of ectopic calcification in plasma, and the concentration of fetuin A is closely associated with protein nutritional status. The purpose of this study is to examine whether the plasma concentration of fetuin A is associated with atherosclerosis and 5-year prognosis in hemodialysis patients.|
Call for more information